Canada Pulmonary Arterial Hypertension Market Size & Outlook
Canada pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Canada pulmonary arterial hypertension market highlights
- The Canada pulmonary arterial hypertension market generated a revenue of USD 448.9 million in 2023 and is expected to reach USD 675.3 million by 2030.
- The Canada market is expected to grow at a CAGR of 6% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 448.9 million |
| Market revenue in 2030 | USD 675.3 million |
| Growth rate | 6% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Canada accounted for 6.1% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 675.3 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.14% in 2023. Horizon Databook has segmented the Canada pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Canada followed by the U.S. which is a growing region for this market. As per Canadian Institute for Health Information (CIHI), the largest population group is beginning to turn 40 years old and more thus being more prone to incidences of pulmonary disorders including PAH. Also, the focus on improving quality of life and using modern technologies are anticipated to assist market growth.
The regulations and incentives for development of orphan drugs are in line with regulations in the U.S. and EU, which is also anticipated to foster market growth in this region. This is expected to help the country’s residents suffering from rare diseases by providing access to the drugs they need. Approximately one out of twelve Canadians have a rare disease.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Canada Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
